Valuation: Insulet Corporation

Market Cap 10.33B 9.27B 8.57B 7.76B 14.5B 984B 14.67B 102B 40.8B 515B 38.76B 37.94B 1,634B P/E 2026 *
24.3x
P/E 2027 * 19.5x
Enterprise Value 10.38B 9.31B 8.61B 7.8B 14.57B 988B 14.74B 103B 41B 517B 38.95B 38.12B 1,642B EV / Sales 2026 *
3.16x
EV / Sales 2027 * 2.68x
Free-Float
97.63%
Yield 2026 *
-
Yield 2027 * -
1 day-0.60%
1 week+4.95%
Current month+14.15%
1 month+11.88%
3 months-11.07%
6 months-18.56%
Current year-47.60%
1 week 145
Extreme 145
150.74
1 month 128.01
Extreme 128.01
150.74
Current year 126.4
Extreme 126.4
299.8
1 year 126.4
Extreme 126.4
354.88
3 years 126.4
Extreme 126.4
354.88
5 years 125.82
Extreme 125.82
354.88
10 years 30.69
Extreme 30.69
354.88
Manager TitleAgeSince
Chief Executive Officer 55 28/04/2025
Director of Finance/CFO 53 30/09/2025
Compliance Officer 50 01/12/2022
Director TitleAgeSince
Director/Board Member 61 27/07/2015
Director/Board Member 54 20/10/2020
Director/Board Member 55 18/10/2021
Date Insider Type Main position Quantity % Market Cap. Importance
1/10/26 Tax

Chief Financial Officer

-1,882 0.0027%
30/9/26 Free

Director

141 0.0002%
30/9/26 Free

Director

178 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
-0.60%+4.95%-54.08%+11.62% 10.33B
-0.45%+2.12%-18.93%+10.54% 178B
+0.86%+2.15%-19.13%+16.07% 117B
+0.88%+1.88%+1.66%+36.51% 116B
+0.79%+0.96%-43.81%+6.28% 91.03B
-0.31%-4.72%-3.36%+72.86% 61.89B
-0.32%-0.19%+10.38%+83.80% 55.85B
+0.07%+0.42%+5.94%-22.43% 53.16B
+0.30%+1.70%-11.26%+43.83% 44.35B
+0.83%+3.08%-3.06%-8.71% 33.59B
Average +0.18%+1.35%-13.57%+25.04% 76.04B
Weighted average by Cap. +0.24%+1.30%-12.97%+24.10%

Financials

2026 *2027 *
Net sales 3.29B 2.95B 2.73B 2.47B 4.61B 313B 4.67B 32.6B 12.98B 164B 12.33B 12.07B 520B 3.73B 3.35B 3.1B 2.8B 5.24B 356B 5.3B 37.02B 14.75B 186B 14.01B 13.71B 591B
Net income 425M 381M 353M 319M 597M 40.5B 604M 4.22B 1.68B 21.19B 1.6B 1.56B 67.27B 534M 479M 443M 401M 749M 50.84B 758M 5.29B 2.11B 26.61B 2B 1.96B 84.46B
Net Debt 49.62M 44.52M 41.16M 37.28M 69.65M 4.73B 70.49M 492M 196M 2.47B 186M 182M 7.85B -322M -289M -267M -242M -452M -30.7B -458M -3.2B -1.27B -16.07B -1.21B -1.18B -51B
Projected Income Statement - Annual - Insulet Corporation
Logo Insulet Corporation
Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (98.7%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (1.3%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). At the end of 2025, the group had 2 production sites located in the United States and in China. The United States account for 72.2% of net sales.
Employees
5,400
Date Price Change Volume
28/10/26 USD 148.93 -0.60% 1,035,225
27/10/26 USD 149.83 +0.38% 943,833
26/10/26 USD 149.26 +0.17% 1,525,635
23/10/26 USD 149.01 +0.60% 803,141
22/10/26 USD 148.12 +4.38% 1,213,882
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - Insulet Corporation
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
148.93USD
Average target price
167.17USD
Spread / Average Target
+12.25%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Insulet Corporation
  1. Stock Market
  2. Stocks
  3. PODD Stock